Linzess vs Trulance: Linaclotide and Plecanatide Peptide Drugs Compared
Linzess vs Trulance compared by peptide structure, approved uses, IBS-C and CIC evidence, diarrhea risk, label warnings and practical differences.
Linzess vs Trulance is a common comparison because both are oral prescription drugs for constipation-related disorders, both act in the gut, and both are peptides rather than conventional small molecules. The similarity is real, but it is easy to overstate.
Linzess is the brand name for linaclotide, a 14-amino acid guanylate cyclase-C agonist. Trulance is the brand name for plecanatide, a 16-amino acid uroguanylin analog that also activates guanylate cyclase-C. Both are designed to work locally in the intestinal lumen, not as systemic hormone peptides.
This comparison is educational and not medical advice. IBS-C, chronic idiopathic constipation and pediatric constipation require diagnosis and individual medical care. Neither drug should be started, stopped, substituted or combined without a qualified clinician.
Quick Comparison
| Question | Linzess | Trulance |
|---|---|---|
| Active ingredient | Linaclotide | Plecanatide |
| Peptide identity | 14-amino acid GC-C agonist | 16-amino acid uroguanylin analog GC-C agonist |
| Adult labeled uses | IBS-C and chronic idiopathic constipation | IBS-C and chronic idiopathic constipation |
| Pediatric label context | Functional constipation in ages 6 to 17; age-specific restrictions apply | Adult-only labeled uses in the current US label |
| Usual adult dosing style | Indication-specific capsule strengths | One 3 mg tablet for adult CIC or IBS-C |
| Absorption | Minimal systemic exposure after oral dosing | Minimal systemic exposure after oral dosing |
| Main safety issue | Diarrhea, severe diarrhea, dehydration risk | Diarrhea and dehydration risk |
| Main comparison caveat | No direct proof that Linzess is broadly superior to Trulance | No direct proof that Trulance is broadly superior to Linzess |
The short version: both are evidence-backed, locally acting gut peptides. The choice is usually about diagnosis, age, label fit, prior response, diarrhea tolerance, insurance coverage, tablet or capsule preference and clinician judgment, not a simple "stronger peptide" ranking.
Why Both Count As Peptide Drugs
Most people encounter peptides through injectable GLP-1 drugs, research vials or cosmetic ingredients. Linzess and Trulance sit in a different category: regulated oral peptide medicines.
Linaclotide was modeled on guanylin and heat-stable enterotoxin biology. It contains three disulfide bonds, which help the molecule keep a compact structure long enough to act in the gut. The Linzess label describes binding to guanylate cyclase-C, or GC-C, on the luminal surface of the intestinal epithelium.
Plecanatide was designed as an analog of uroguanylin, a human intestinal peptide hormone. The Trulance label also describes local GC-C activation, with negligible systemic availability after oral dosing.
That local action is the key. These drugs are not comparable to GLP-1 receptor agonists, not weight-loss peptides and not general "gut healing" protocols. For broader chemistry context, see what are peptides and the oral peptides guide.
Mechanism: Same Target, Different Molecules
Both drugs activate GC-C on the intestinal lining. GC-C activation raises cyclic GMP, which drives chloride and bicarbonate secretion through CFTR-related pathways and increases fluid movement into the intestinal lumen. More intestinal fluid and altered transit can help constipation endpoints in selected patients. Extracellular cyclic GMP is also discussed as part of the abdominal-pain mechanism in IBS-C, although symptom response is still measured clinically, not assumed from mechanism alone.
The drugs differ structurally:
| Feature | Linaclotide | Plecanatide |
|---|---|---|
| Peptide length | 14 amino acids | 16 amino acids |
| Biological design | Guanylin and enterotoxin-like GC-C agonist | Uroguanylin analog |
| Form | Oral capsule | Oral tablet |
| Practical implication | Multiple adult and pediatric label strengths | Simple adult 3 mg tablet label |
Plecanatide is often described as pH-sensitive because it was built around uroguanylin-like behavior. That is a biologically plausible distinction, but it does not automatically prove a better real-world outcome for every patient. Clinical evidence still has to come from trials and labels.
Evidence For Linzess
Linaclotide has placebo-controlled evidence in both chronic idiopathic constipation and IBS-C. In chronic constipation, two randomized trials published in the New England Journal of Medicine studied linaclotide against placebo and found higher complete spontaneous bowel movement responder rates with linaclotide.
In IBS-C, two phase 3 trials published in the American Journal of Gastroenterology evaluated symptom endpoints across 12-week and 26-week timeframes. They measured abdominal pain and bowel-movement response, not a vague digestive wellness outcome. The trials support a real effect in selected adult IBS-C populations, while diarrhea remained the central adverse event.
The Linzess label also has pediatric content. It includes functional constipation in patients aged 6 to 17 years and carries strong warnings for younger children. That pediatric distinction makes Linzess different from Trulance in current US labeling, but it does not mean it is broadly appropriate for every child with constipation.
For a standalone evidence profile, see the full linaclotide peptide guide.
Evidence For Trulance
Plecanatide also has randomized phase 3 evidence. In chronic idiopathic constipation, trials by Miner and DeMicco and colleagues reported higher durable complete spontaneous bowel movement response rates with plecanatide than placebo. In IBS-C, two phase 3 randomized trials evaluated plecanatide 3 mg and 6 mg against placebo and reported improvements in abdominal pain and bowel symptom endpoints.
The US label for Trulance is simpler in one practical way: the adult dose is 3 mg once daily for both chronic idiopathic constipation and IBS-C. That simplicity does not remove the need for patient selection, contraindication review and monitoring for diarrhea.
The strongest claim is narrow: Trulance is an FDA-approved, adult, locally acting GC-C agonist for CIC and IBS-C. It is not a microbiome repair drug, systemic peptide hormone or anti-aging intervention.
For structured database context, see plecanatide.
Is One Better?
There is no clean universal winner. The best evidence comparison is indirect because the main trial programs compared each drug with placebo rather than directly randomizing Linzess against Trulance in a large outcomes trial.
A systematic review and meta-analysis of GC-C agonists found that the class has evidence for IBS-C and chronic idiopathic constipation, but indirect comparison is not the same as a head-to-head superiority trial. Different trial designs, entry criteria, doses, endpoints and adverse-event reporting can distort simple rankings.
Useful comparison questions are more practical:
| Decision point | Why it matters |
|---|---|
| Diagnosis | IBS-C and chronic idiopathic constipation overlap, but they are not identical conditions. |
| Age | Linzess has current pediatric functional-constipation labeling; Trulance is adult-labeled. |
| Dose format | Linzess uses indication-specific capsule strengths; Trulance uses a 3 mg adult tablet. |
| Diarrhea history | Both can cause diarrhea, and severe diarrhea can lead to dehydration. |
| Obstruction risk | Both labels contraindicate use in known or suspected mechanical gastrointestinal obstruction. |
| Coverage and access | Formulary rules can determine which option is actually available. |
Readers looking at "gut peptide" claims should also compare these drugs with non-GC-C gut peptides such as teduglutide, not because they treat the same problem, but because it shows why the word peptide does not define a shared effect.
Safety Comparison
The safety overlap is substantial. Both labels carry a boxed warning related to serious dehydration risk in young children, and both contraindicate use in known or suspected mechanical gastrointestinal obstruction.
The practical adverse effect is diarrhea. Mild diarrhea may be expected with a secretagogue mechanism, but severe diarrhea is clinically different because it can cause dehydration, dizziness, electrolyte problems or treatment discontinuation. Anyone with frailty, limited fluid intake, kidney disease, multiple gastrointestinal conditions or complex medications needs individualized medical review.
The low systemic absorption is reassuring in one sense, but it should not be misread as risk-free. Local intestinal drugs can still produce clinically important fluid shifts.
Claim Checks
| Claim | Better reading |
|---|---|
| "Trulance is the natural peptide version." | It is a synthetic uroguanylin analog, not simply natural uroguanylin. |
| "Linzess is stronger, so it works better." | Higher or different dosing does not prove better outcomes across patients. |
| "Both are gut-health peptides." | They are prescription GC-C agonists for labeled constipation-related disorders. |
| "Minimal absorption means no side effects." | The main side effect is local intestinal fluid movement, not systemic exposure. |
| "You can choose by peptide length." | Trial population, label, contraindications and tolerability matter more than amino acid count. |
If a comparison ignores label context, pediatric warnings, obstruction contraindications and the lack of broad head-to-head superiority evidence, it is probably too thin to guide a medical decision.
Bottom Line
Linzess and Trulance are two legitimate oral peptide drugs in the same GC-C agonist class. Linzess contains linaclotide; Trulance contains plecanatide. Both have placebo-controlled human evidence in adult constipation-related disorders, and both work locally in the gut with minimal systemic absorption.
The real comparison is practical and evidence-bound. Linzess has multiple strengths and current pediatric functional-constipation labeling. Trulance has a simple adult 3 mg tablet label. Both can cause diarrhea and dehydration, both have pediatric boxed-warning language, and neither should be framed as a broad gut-health peptide.
For wider context, use the gut health peptide guide and the peptide half-life guide to separate local gut action from systemic peptide pharmacology.
References
Lembo AJ, et al. Two randomized trials of linaclotide for chronic constipation.
Chey WD, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Miner PB Jr, et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
DeMicco M, et al. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
Brenner DM, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Luthra P, et al. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.